NCT04971226 2026-04-06A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CPNovartisPhase 3 Active not recruiting405 enrolled 18 charts 3 FDA
NCT02081378 2024-03-18A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALLNovartisPhase 1 Completed326 enrolled 2 FDA
NCT01077544 2020-12-29A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)NovartisPhase 1 Completed15 enrolled 20 charts 2 FDA